Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Engain Co. Ltd. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, KONOPELSKI SNAVEL, SARA ELIZABETH. As the busiest examiner for the company, she holds the 1 busiest examiner pending office action. This represents a very focused and singular prosecution effort. The entire pending portfolio is located within 1 distinct art unit.
For a practitioner, this means that the outcome of the company's current patent efforts is entirely dependent on the decisions made within this 1 distinct art unit and by this 1 distinct examiner. There is no diversity in the prosecution profile to mitigate the risk of a single examiner's perspective. With only 1 pending office action, the current workload is light, but the concentration of that workload means that every interaction with the 1 distinct examiner is critical for the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284374 | EMBOLIC MATERIAL FOR RELIEVING OR TREATING MUSCULOSKELETAL PAIN COMPRISING FAST DISSOLVING GELATIN PARTICLES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284374 | EMBOLIC MATERIAL FOR RELIEVING OR TREATING MUSCULOSKELETAL PAIN COMPRISING FAST DISSOLVING GELATIN PARTICLES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284374 | EMBOLIC MATERIAL FOR RELIEVING OR TREATING MUSCULOSKELETAL PAIN COMPRISING FAST DISSOLVING GELATIN PARTICLES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103§112 | Final Rejection | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial